Biotechnology companies whose drug discovery is built around machine learning, computational chemistry, protein design or automated biology. Most are clinical-stage and earn revenue from partnerships rather than product sales.
Representative public companies: Recursion Pharmaceuticals (RXRX), Absci (ABSI), Relay Therapeutics (RLAY), AbCellera Biologics (ABCL), Ginkgo Bioworks (DNA), Beam Therapeutics (BEAM). Named for context only, not as recommendations.
Research current as of September 12, 2026 · Adoption stage: Scaling deployments
AI-first drug discovery reached its first late-stage test in 2026, though no AI-discovered drug has been approved. On July 7, 2026, Insilico Medicine initiated a Phase III trial of rentosertib for idiopathic pulmonary fibrosis, with 320 participants at 47 centers in China. Most AI-native companies remain earlier: Recursion's IND-cleared REC-7735 is slated for a Phase 1/2 start in the second half of 2026, and Alphabet's Isomorphic Labs moved its first-trial target to the end of 2026. Private money is flowing to platforms, with Chai Discovery raising $400 million at a $3.8 billion valuation in July 2026. Listed names are conserving cash: Recursion lowered its 2026 cash operating expense guidance by $15 million to $375 million, and Schrodinger is seeking partners for mid- and late-stage development of its clinical programs.
| Company | What was deployed | Date |
|---|---|---|
| Insilico Medicine (private; Hong Kong-listed plans not verified) | Initiated a randomized, double-blind, placebo-controlled Phase III trial of rentosertib, a TNIK inhibitor developed using generative AI, in idiopathic pulmonary fibrosis Earlier Phase IIa: 60 mg once-daily arm showed mean FVC change of +98.4 mL at 12 weeks versus -20.3 mL for placebo; Phase III has not read out |
2026-07-07[1] |
| Recursion Pharmaceuticals (RXRX) | AI-designed REC-7735, a mutant-selective PI3K-alpha H1047R inhibitor, cleared its IND; Genentech advanced the first neuroscience target from the collaboration into a joint early discovery program Recursion has received $216 million in upfront and milestone payments from Genentech/Roche; cash of $556.8 million at June 30, 2026 with runway into early 2028 |
2026-08-05[2] |
| Chai Discovery (private), with Eli Lilly, Pfizer and other partners | Generative models (Chai-2, Chai-3) for de novo antibody and molecule design used by pharma partners Company says Chai-2 was the first zero-shot platform for fully de novo antibody design to achieve double-digit experimental success rates (company-reported; no Chai-designed molecule reported in clinical trials) |
2026-07-14[3] |
| Schrodinger (SDGR) | Physics-based and machine learning drug design software sold to pharma, plus in-house clinical programs SGR-1505 (MALT1) and SGR-3515 (Wee1/Myt1) Q1 2026 software revenue $35.6 million, down 21%; SGR-3515 Phase 1 showed a 65% disease control rate; company exploring partnerships for mid- and late-stage development |
2026-05-05[4] |
| Isomorphic Labs (Alphabet, GOOGL) | AlphaFold-based drug design unit preparing its first clinical trials, prioritizing oncology | 2026-01-20[5] |
Projections grounded in what is happening now, not certainties. Each one names the signal that would confirm it.
AI-native platforms now validated at production scale. Recursion: 12-18mo IND timeline (vs traditional 2.5-4yr), 50+ petabytes proprietary data, BioHive-2 biopharma supercomputer.
Insilico: 5,000 novel peptides in 72hrs, 14/20 showed activity. AlphaFold at 0.96Å eliminated crystallography bottleneck entirely.
Current at 48% — AI IS the business model. Still zero FDA approvals as of early 2026 but first wave approaching trials.
Binary risk + acquihire exit pattern unchanged.
A score of 1.00 = no change.
>1.00 means AI (net) boosts this industry's relative value.
<1.00 means AI (net) erodes it.
These are relative scores — how this industry's share of the economy shifts in relation to all 31 industries we track.
| Timeframe | Score | Range | In Plain English |
|---|---|---|---|
| 1 Year | 1.17 | 1.14 – 1.21 | AI tailwind (+17%) |
| 2 Years | 1.32 | 1.26 – 1.38 | AI tailwind (+32%) |
| 3 Years | 1.68 | 1.55 – 1.80 | AI tailwind (+68%) |
| 5 Years | 2.49 | 2.28 – 2.70 | AI tailwind (+149%) |
| 10 Years | 3.05 | 2.81 – 3.29 | AI tailwind (+205%) |
The same engine run under three sets of assumptions. The spread between the rows shows the uncertainty. It is not a forecast of which one happens.
| Scenario | 1 yr | 2 yr | 3 yr | 5 yr | 10 yr | Rank |
|---|---|---|---|---|---|---|
| Boom Faster AI progress, energy breakthroughs | 1.19 | 1.34 | 1.77 | 2.83 | 3.55 | #1 |
| Base Base case AI progress, current trajectory energy | 1.17 | 1.32 | 1.68 | 2.49 | 3.05 | #1 |
| Doom Slower AI progress, constrained energy, market correction | 1.11 | 1.27 | 1.57 | 2.16 | 2.58 | #1 |
Each component is scored from research, weighted differently at each time horizon, and added together:
Then cascaded through 205 cross-industry relationships.
Built from earnings calls, patent filings, regulatory documents, deployment disclosures and peer-reviewed research. 205 mapped cross-industry relationships. Recalibrated continuously since February 2026, with every parameter change logged.
Refreshed with every major development. Real deployment numbers, quarterly earnings data, regulatory shifts (EU AI Act, export controls), and macro conditions like the energy bottleneck. Not a static model — a living one.
This report uses: Base case AI development pace and Current trajectory energy trajectory. Members can adjust both and see how scores change in real time.
When AI changes these industries, it ripples into PHARMA - Biotech & AI Drug Discovery.
| Industry | Effect | Strength | Timing |
|---|---|---|---|
|
SEMICONDUCTORS - Chip Design & Fabless
AI growth in SEMICONDUCTORS - Chip Design & Fabless creates demand or opportunities that benefit PHARMA - Biotech & AI Drug Discovery
|
Positive | 95% | Medium-term |
|
PHARMA - Big Pharma
AI growth in PHARMA - Big Pharma creates demand or opportunities that benefit PHARMA - Biotech & AI Drug Discovery
|
Positive | 85% | Medium-term |
|
PHARMA - Life Sciences Tools & Services
AI growth in PHARMA - Life Sciences Tools & Services creates demand or opportunities that benefit PHARMA - Biotech & AI Drug Discovery
|
Positive | 70% | Medium-term |
|
Materials
AI growth in Materials creates demand or opportunities that benefit PHARMA - Biotech & AI Drug Discovery
|
Positive | 55% | Long-term |
|
SEMICONDUCTORS - Foundry & Equipment
AI growth in SEMICONDUCTORS - Foundry & Equipment creates demand or opportunities that benefit PHARMA - Biotech & AI Drug Discovery
|
Positive | 50% | Medium-term |
When AI changes PHARMA - Biotech & AI Drug Discovery, 8 other industries feel it:
See how all 31 industries compare in our Full AI Market Cascade Dashboard